<DOC>
	<DOCNO>NCT00600119</DOCNO>
	<brief_summary>Study ( 07-IN-NX003 ) Phase 2 , multi-center , placebo-controlled , double-blind , randomize , dose-escalation trial . It design investigate safety , efficacy tolerability NKTR-118 ( PEG-naloxol ) patient opioid-induced constipation ( OIC ) clinical manifestation opioid-induced bowel dysfunction ( OBD ) . The objective study evaluate safety , effectiveness pharmacokinetics NKTR-118 4 different dos .</brief_summary>
	<brief_title>A Phase 2 , Double-Blind , Multiple-Dose Escalation Study Evaluate NKTR-118 ( Oral PEG-Naloxol ) Patients With Opioid-Induced Constipation ( OIC )</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Naloxegol</mesh_term>
	<criteria>Main 18 year age old , male female Receiving stable opioid regimen Documented opioidinduced constipation Willingness stop laxatives bowel regimen . The use constipation rescue medication allow study . Main Life expectancy le 6 month Active substance abuse Fecal incontinence , irritable bowel syndrome , inflammatory bowel disease , active medical disorder associate diarrhea intermittent loose stool constipation Pregnant breastfeed Any receipt investigational medication within 30 day screen History presence specific cardiac , neurologic , endocrine and/or psychiatric condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>NKTR , constipation , opioid , induce , bowel , dysfunction , Naloxol , Naloxone , Narcan , PEG naloxol , OIC , OBD , Nektar</keyword>
</DOC>